Product Wiki · Recalls · EU Safety Gate (RAPEX)

Pixo Pods — recall SR/00822/25

EU Safety Gate (RAPEX) · Malta · 2025-03-07 · Serious risk

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
SR/00822/25
Date of alert
2025-03-07
Country / jurisdiction
Malta
Risk level
Serious risk
Risk type
Chemical
Brand
Aspire
Product category
Chemical products
Product type
Electronic cigarette cartridge
Barcode (EAN/GTIN)
6958947186940
Reported risk: The product is not equipped with a child-resistant fastening, which creates a health risk when in the hands of children. Moreover, the product has an excessive amount of nicotine-containing liquid (declared value: 3ml). This could lead to the accidental consumption of a high dose of nicotine. Nicotine is acutely toxic and can endanger the user’s safety, notably if the product comes into contact with the skin or is ingested.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator to whom the measure were ordered
Other
Category of measure
Import rejected at border
Date of entry into force
21/02/2025
Type of economic operator taking notified measure
Manufacturer
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10093457

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.